Click for best price

Drugs for Oncology Market Size, Share 2023

Market Analysis and Insights: Global Drugs for Oncology Market

The global Drugs for Oncology market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.

With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Drugs for Oncology market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Drugs for Oncology market in terms of revenue.

On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Drugs for Oncology market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Drugs for Oncology market.

Global Drugs for Oncology Scope and Market Size

Drugs for Oncology market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Drugs for Oncology market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2018-2032.

Segment by Type

Chemotherapy

Targeted Therapy

Immunotherapy (Biologic Therapy)

Hormonal Therapy

Others

Segment by Application

Blood Cancer

Breast Cancer

Gastrointestinal Cancer

Prostate Cancer

Respiratory/Lung Cancer

Others

By Region

North America

United States

Canada

Europe

Germany

France

Italy

Russia

Nordic Countries

Rest of Europe

Asia-Pacific

China

Japan

South Korea

Southeast Asia

India

Australia

Rest of Asia

Latin America

Mexico

Brazil

Rest of Latin America

Middle East & Africa

Turkey

Saudi Arabia

UAE

Rest of MEA

By Company

Roche

Celgene

Novartis

Bristol-Myers Squibb

Johnson & Johnson

Merck & Co.

AstraZeneca

Pfizer

Amgen

Eli Lilly

AbbVie

Takeda

Astellas

Ipsen

Sanofi

Bayer

Biogen Idec

Teva

Otsuka

Eisai

Merck KGaA

Gilead Sciences

The information for each competitor/Company Profile includes:

Company Overview
Business Strategy
Key Product Offerings
Financial Performance
Key Performance Indicators
Risk Analysis
Recent Development
Regional Presence
SWOT Analysis

The content of the study subjects includes a total of 15 chapters:

Chapter 1, describes Drugs for Oncology product scope, market overview, market opportunities, market driving force, and market risks.

Chapter 2, profiles the top manufacturers of Drugs for Oncology, with price, sales, revenue, and global market share of Drugs for Oncology from 2019 to 2022.

Chapter 3, the Drugs for Oncology competitive situation, sales, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.

Chapter 4, the Drugs for Oncology breakdown data are shown at the regional level, to show the sales, revenue and growth by regions, from 2017 to 2028.

Chapters 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, and application, from 2017 to 2028.

Chapters 7, 8, 9, 10, and 11, to break the sales data at the country level, with sales, revenue, and market share for key countries in the world, from 2017 to 2022. and the Drugs for Oncology market forecast, by regions, type, and application, with sales and revenue, from 2023 to 2028.

Chapter 12, the key raw materials and key suppliers, and industry chain of Drugs for Oncology.

Chapter 13, 14, and 15, to describe Drugs for Oncology sales channel, distributors, customers, research findings and conclusion, appendix and data source.

Key Indicators Analysed:

Market Players & Competitor Analysis: The report covers the key players of the industry including Company Profile, Product Specifications, Production Capacity/Sales, Revenue, Price and Gross Margin 2016-2027 & Sales with a thorough analysis of the market?s competitive landscape and detailed information on vendors and comprehensive details of factors that will challenge the growth of major market vendors.
Global and Regional Market Analysis: The report includes Global & Regional market status and outlook 2016-2027. Further the report provides break down details about each region & countries covered in the report. Identifying its sales, sales volume & revenue forecast. With detailed analysis by types and applications.
Market Trends: Market key trends which include Increased Competition and Continuous Innovations.
Opportunities and Drivers: Identifying the Growing Demands and New Technology
Porters Five Force Analysis: The report provides with the state of competition in industry depending on five basic forces: threat of new entrants, bargaining power of suppliers, bargaining power of buyers, threat of substitute products or services, and existing industry rivalry.

Reasons to Purchase this Report:

Estimates 2022-2027 2021-2025 Drugs for Oncology Report on, Status and Forecast, by Players, Types and Applications market development trends with the recent trends and SWOT analysis
Market dynamics scenario, along with growth opportunities of the market in the years to come
Market segmentation analysis including qualitative and quantitative research incorporating the impact of economic and policy aspects
Regional and country level analysis integrating the demand and supply forces that are influencing the growth of the market.
Market value (USD Million) and volume (Units Million) data for each segment and sub-segment
Competitive landscape involving the market share of major players, along with the new projects and strategies adopted by players in the past five years
Comprehensive company profiles covering the product offerings, key financial information, recent developments, SWOT analysis, and strategies employed by the major market players
1-year analyst support, along with the data support in excel format.

Research Methodology:

The research methodology used to estimate and forecast this market begins by capturing the revenues of the key players and their shares in the market. Various secondary sources such as press releases, annual reports, non-profit organizations, industry associations, governmental agencies and customs data, have been used to identify and collect information useful for this extensive commercial study of the market. Calculations based on this led to the overall market size. After arriving at the overall market size, the total market has been split into several segments and subsegments, which have then been verified through primary research by conducting extensive interviews with industry experts such as CEOs, VPs, directors, and executives. The data triangulation and market breakdown procedures have been employed to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments.

Report Attributes	Report Details
Report Title	Global Drugs for Oncology Market Research Report 2023
Historical Year	2018 to 2022 (Data from 2010 can be provided as per availability)
Base Year	2022
Forecast Year	2030
Number of Pages	110 Pages
Customization Available	Yes, the report can be customized as per your need.

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Drugs for Oncology Market Size Growth Rate by Type: 2018 VS 2022 VS 2032
1.2.2 Chemotherapy
1.2.3 Targeted Therapy
1.2.4 Immunotherapy (Biologic Therapy)
1.2.5 Hormonal Therapy
1.2.6 Others
1.3 Market by Application
1.3.1 Global Drugs for Oncology Market Share by Application: 2018 VS 2022 VS 2032
1.3.2 Blood Cancer
1.3.3 Breast Cancer
1.3.4 Gastrointestinal Cancer
1.3.5 Prostate Cancer
1.3.6 Respiratory/Lung Cancer
1.3.7 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Drugs for Oncology Market Perspective (2018-2032)
2.2 Drugs for Oncology Growth Trends by Region
2.2.1 Drugs for Oncology Market Size by Region: 2018 VS 2022 VS 2032
2.2.2 Drugs for Oncology Historic Market Size by Region (2018-2023)
2.2.3 Drugs for Oncology Forecasted Market Size by Region (2023-2032)
2.3 Drugs for Oncology Market Dynamics
2.3.1 Drugs for Oncology Industry Trends
2.3.2 Drugs for Oncology Market Drivers
2.3.3 Drugs for Oncology Market Challenges
2.3.4 Drugs for Oncology Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Drugs for Oncology Players by Revenue
3.1.1 Global Top Drugs for Oncology Players by Revenue (2018-2023)
3.1.2 Global Drugs for Oncology Revenue Market Share by Players (2018-2023)
3.2 Global Drugs for Oncology Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Drugs for Oncology Revenue
3.4 Global Drugs for Oncology Market Concentration Ratio
3.4.1 Global Drugs for Oncology Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Drugs for Oncology Revenue in 2022
3.5 Drugs for Oncology Key Players Head office and Area Served
3.6 Key Players Drugs for Oncology Product Solution and Service
3.7 Date of Enter into Drugs for Oncology Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Drugs for Oncology Breakdown Data by Type
4.1 Global Drugs for Oncology Historic Market Size by Type (2018-2023)
4.2 Global Drugs for Oncology Forecasted Market Size by Type (2023-2032)
5 Drugs for Oncology Breakdown Data by Application
5.1 Global Drugs for Oncology Historic Market Size by Application (2018-2023)
5.2 Global Drugs for Oncology Forecasted Market Size by Application (2023-2032)
6 North America
6.1 North America Drugs for Oncology Market Size (2018-2032)
6.2 North America Drugs for Oncology Market Size by Country (2018-2023)
6.3 North America Drugs for Oncology Market Size by Country (2023-2032)
6.4 United States
6.5 Canada
7 Europe
7.1 Europe Drugs for Oncology Market Size (2018-2032)
7.2 Europe Drugs for Oncology Market Size by Country (2018-2023)
7.3 Europe Drugs for Oncology Market Size by Country (2023-2032)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Drugs for Oncology Market Size (2018-2032)
8.2 Asia-Pacific Drugs for Oncology Market Size by Country (2018-2023)
8.3 Asia-Pacific Drugs for Oncology Market Size by Country (2023-2032)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia
9 Latin America
9.1 Latin America Drugs for Oncology Market Size (2018-2032)
9.2 Latin America Drugs for Oncology Market Size by Country (2018-2023)
9.3 Latin America Drugs for Oncology Market Size by Country (2023-2032)
9.4 Mexico
9.5 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Drugs for Oncology Market Size (2018-2032)
10.2 Middle East & Africa Drugs for Oncology Market Size by Country (2018-2023)
10.3 Middle East & Africa Drugs for Oncology Market Size by Country (2023-2032)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE
11 Key Players Profiles
11.1 Roche
11.1.1 Roche Company Detail
11.1.2 Roche Business Overview
11.1.3 Roche Drugs for Oncology Introduction
11.1.4 Roche Revenue in Drugs for Oncology Business (2018-2023)
11.1.5 Roche Recent Development
11.2 Celgene
11.2.1 Celgene Company Detail
11.2.2 Celgene Business Overview
11.2.3 Celgene Drugs for Oncology Introduction
11.2.4 Celgene Revenue in Drugs for Oncology Business (2018-2023)
11.2.5 Celgene Recent Development
11.3 Novartis
11.3.1 Novartis Company Detail
11.3.2 Novartis Business Overview
11.3.3 Novartis Drugs for Oncology Introduction
11.3.4 Novartis Revenue in Drugs for Oncology Business (2018-2023)
11.3.5 Novartis Recent Development
11.4 Bristol-Myers Squibb
11.4.1 Bristol-Myers Squibb Company Detail
11.4.2 Bristol-Myers Squibb Business Overview
11.4.3 Bristol-Myers Squibb Drugs for Oncology Introduction
11.4.4 Bristol-Myers Squibb Revenue in Drugs for Oncology Business (2018-2023)
11.4.5 Bristol-Myers Squibb Recent Development
11.5 Johnson & Johnson
11.5.1 Johnson & Johnson Company Detail
11.5.2 Johnson & Johnson Business Overview
11.5.3 Johnson & Johnson Drugs for Oncology Introduction
11.5.4 Johnson & Johnson Revenue in Drugs for Oncology Business (2018-2023)
11.5.5 Johnson & Johnson Recent Development
11.6 Merck & Co.
11.6.1 Merck & Co. Company Detail
11.6.2 Merck & Co. Business Overview
11.6.3 Merck & Co. Drugs for Oncology Introduction
11.6.4 Merck & Co. Revenue in Drugs for Oncology Business (2018-2023)
11.6.5 Merck & Co. Recent Development
11.7 AstraZeneca
11.7.1 AstraZeneca Company Detail
11.7.2 AstraZeneca Business Overview
11.7.3 AstraZeneca Drugs for Oncology Introduction
11.7.4 AstraZeneca Revenue in Drugs for Oncology Business (2018-2023)
11.7.5 AstraZeneca Recent Development
11.8 Pfizer
11.8.1 Pfizer Company Detail
11.8.2 Pfizer Business Overview
11.8.3 Pfizer Drugs for Oncology Introduction
11.8.4 Pfizer Revenue in Drugs for Oncology Business (2018-2023)
11.8.5 Pfizer Recent Development
11.9 Amgen
11.9.1 Amgen Company Detail
11.9.2 Amgen Business Overview
11.9.3 Amgen Drugs for Oncology Introduction
11.9.4 Amgen Revenue in Drugs for Oncology Business (2018-2023)
11.9.5 Amgen Recent Development
11.10 Eli Lilly
11.10.1 Eli Lilly Company Detail
11.10.2 Eli Lilly Business Overview
11.10.3 Eli Lilly Drugs for Oncology Introduction
11.10.4 Eli Lilly Revenue in Drugs for Oncology Business (2018-2023)
11.10.5 Eli Lilly Recent Development
11.11 AbbVie
11.11.1 AbbVie Company Detail
11.11.2 AbbVie Business Overview
11.11.3 AbbVie Drugs for Oncology Introduction
11.11.4 AbbVie Revenue in Drugs for Oncology Business (2018-2023)
11.11.5 AbbVie Recent Development
11.12 Takeda
11.12.1 Takeda Company Detail
11.12.2 Takeda Business Overview
11.12.3 Takeda Drugs for Oncology Introduction
11.12.4 Takeda Revenue in Drugs for Oncology Business (2018-2023)
11.12.5 Takeda Recent Development
11.13 Astellas
11.13.1 Astellas Company Detail
11.13.2 Astellas Business Overview
11.13.3 Astellas Drugs for Oncology Introduction
11.13.4 Astellas Revenue in Drugs for Oncology Business (2018-2023)
11.13.5 Astellas Recent Development
11.14 Ipsen
11.14.1 Ipsen Company Detail
11.14.2 Ipsen Business Overview
11.14.3 Ipsen Drugs for Oncology Introduction
11.14.4 Ipsen Revenue in Drugs for Oncology Business (2018-2023)
11.14.5 Ipsen Recent Development
11.15 Sanofi
11.15.1 Sanofi Company Detail
11.15.2 Sanofi Business Overview
11.15.3 Sanofi Drugs for Oncology Introduction
11.15.4 Sanofi Revenue in Drugs for Oncology Business (2018-2023)
11.15.5 Sanofi Recent Development
11.16 Bayer
11.16.1 Bayer Company Detail
11.16.2 Bayer Business Overview
11.16.3 Bayer Drugs for Oncology Introduction
11.16.4 Bayer Revenue in Drugs for Oncology Business (2018-2023)
11.16.5 Bayer Recent Development
11.17 Biogen Idec
11.17.1 Biogen Idec Company Detail
11.17.2 Biogen Idec Business Overview
11.17.3 Biogen Idec Drugs for Oncology Introduction
11.17.4 Biogen Idec Revenue in Drugs for Oncology Business (2018-2023)
11.17.5 Biogen Idec Recent Development
11.18 Teva
11.18.1 Teva Company Detail
11.18.2 Teva Business Overview
11.18.3 Teva Drugs for Oncology Introduction
11.18.4 Teva Revenue in Drugs for Oncology Business (2018-2023)
11.18.5 Teva Recent Development
11.19 Otsuka
11.19.1 Otsuka Company Detail
11.19.2 Otsuka Business Overview
11.19.3 Otsuka Drugs for Oncology Introduction
11.19.4 Otsuka Revenue in Drugs for Oncology Business (2018-2023)
11.19.5 Otsuka Recent Development
11.20 Eisai
11.20.1 Eisai Company Detail
11.20.2 Eisai Business Overview
11.20.3 Eisai Drugs for Oncology Introduction
11.20.4 Eisai Revenue in Drugs for Oncology Business (2018-2023)
11.20.5 Eisai Recent Development
11.21 Merck KGaA
11.21.1 Merck KGaA Company Detail
11.21.2 Merck KGaA Business Overview
11.21.3 Merck KGaA Drugs for Oncology Introduction
11.21.4 Merck KGaA Revenue in Drugs for Oncology Business (2018-2023)
11.21.5 Merck KGaA Recent Development
11.22 Gilead Sciences
11.22.1 Gilead Sciences Company Detail
11.22.2 Gilead Sciences Business Overview
11.22.3 Gilead Sciences Drugs for Oncology Introduction
11.22.4 Gilead Sciences Revenue in Drugs for Oncology Business (2018-2023)
11.22.5 Gilead Sciences Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

LIST OF TABLES & FIGURES

List of Tables
Table 1. Global Drugs for Oncology Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2032
Table 2. Key Players of Chemotherapy
Table 3. Key Players of Targeted Therapy
Table 4. Key Players of Immunotherapy (Biologic Therapy)
Table 5. Key Players of Hormonal Therapy
Table 6. Key Players of Others
Table 7. Global Drugs for Oncology Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2032
Table 8. Global Drugs for Oncology Market Size by Region (US$ Million): 2018 VS 2022 VS 2032
Table 9. Global Drugs for Oncology Market Size by Region (2018-2023) & (US$ Million)
Table 10. Global Drugs for Oncology Market Share by Region (2018-2023)
Table 11. Global Drugs for Oncology Forecasted Market Size by Region (2023-2032) & (US$ Million)
Table 12. Global Drugs for Oncology Market Share by Region (2023-2032)
Table 13. Drugs for Oncology Market Trends
Table 14. Drugs for Oncology Market Drivers
Table 15. Drugs for Oncology Market Challenges
Table 16. Drugs for Oncology Market Restraints
Table 17. Global Drugs for Oncology Revenue by Players (2018-2023) & (US$ Million)
Table 18. Global Drugs for Oncology Market Share by Players (2018-2023)
Table 19. Global Top Drugs for Oncology Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Drugs for Oncology as of 2022)
Table 20. Ranking of Global Top Drugs for Oncology Companies by Revenue (US$ Million) in 2022
Table 21. Global 5 Largest Players Market Share by Drugs for Oncology Revenue (CR5 and HHI) & (2018-2023)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Drugs for Oncology Product Solution and Service
Table 24. Date of Enter into Drugs for Oncology Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Drugs for Oncology Market Size by Type (2018-2023) & (US$ Million)
Table 27. Global Drugs for Oncology Revenue Market Share by Type (2018-2023)
Table 28. Global Drugs for Oncology Forecasted Market Size by Type (2023-2032) & (US$ Million)
Table 29. Global Drugs for Oncology Revenue Market Share by Type (2023-2032)
Table 30. Global Drugs for Oncology Market Size by Application (2018-2023) & (US$ Million)
Table 31. Global Drugs for Oncology Revenue Market Share by Application (2018-2023)
Table 32. Global Drugs for Oncology Forecasted Market Size by Application (2023-2032) & (US$ Million)
Table 33. Global Drugs for Oncology Revenue Market Share by Application (2023-2032)
Table 34. North America Drugs for Oncology Market Size by Country (2018-2023) & (US$ Million)
Table 35. North America Drugs for Oncology Market Size by Country (2023-2032) & (US$ Million)
Table 36. Europe Drugs for Oncology Market Size by Country (2018-2023) & (US$ Million)
Table 37. Europe Drugs for Oncology Market Size by Country (2023-2032) & (US$ Million)
Table 38. Asia-Pacific Drugs for Oncology Market Size by Region (2018-2023) & (US$ Million)
Table 39. Asia-Pacific Drugs for Oncology Market Size by Region (2023-2032) & (US$ Million)
Table 40. Latin America Drugs for Oncology Market Size by Country (2018-2023) & (US$ Million)
Table 41. Latin America Drugs for Oncology Market Size by Country (2023-2032) & (US$ Million)
Table 42. Middle East & Africa Drugs for Oncology Market Size by Country (2018-2023) & (US$ Million)
Table 43. Middle East & Africa Drugs for Oncology Market Size by Country (2023-2032) & (US$ Million)
Table 44. Roche Company Detail
Table 45. Roche Business Overview
Table 46. Roche Drugs for Oncology Product
Table 47. Roche Revenue in Drugs for Oncology Business (2018-2023) & (US$ Million)
Table 48. Roche Recent Development
Table 49. Celgene Company Detail
Table 50. Celgene Business Overview
Table 51. Celgene Drugs for Oncology Product
Table 52. Celgene Revenue in Drugs for Oncology Business (2018-2023) & (US$ Million)
Table 53. Celgene Recent Development
Table 54. Novartis Company Detail
Table 55. Novartis Business Overview
Table 56. Novartis Drugs for Oncology Product
Table 57. Novartis Revenue in Drugs for Oncology Business (2018-2023) & (US$ Million)
Table 58. Novartis Recent Development
Table 59. Bristol-Myers Squibb Company Detail
Table 60. Bristol-Myers Squibb Business Overview
Table 61. Bristol-Myers Squibb Drugs for Oncology Product
Table 62. Bristol-Myers Squibb Revenue in Drugs for Oncology Business (2018-2023) & (US$ Million)
Table 63. Bristol-Myers Squibb Recent Development
Table 64. Johnson & Johnson Company Detail
Table 65. Johnson & Johnson Business Overview
Table 66. Johnson & Johnson Drugs for Oncology Product
Table 67. Johnson & Johnson Revenue in Drugs for Oncology Business (2018-2023) & (US$ Million)
Table 68. Johnson & Johnson Recent Development
Table 69. Merck & Co. Company Detail
Table 70. Merck & Co. Business Overview
Table 71. Merck & Co. Drugs for Oncology Product
Table 72. Merck & Co. Revenue in Drugs for Oncology Business (2018-2023) & (US$ Million)
Table 73. Merck & Co. Recent Development
Table 74. AstraZeneca Company Detail
Table 75. AstraZeneca Business Overview
Table 76. AstraZeneca Drugs for Oncology Product
Table 77. AstraZeneca Revenue in Drugs for Oncology Business (2018-2023) & (US$ Million)
Table 78. AstraZeneca Recent Development
Table 79. Pfizer Company Detail
Table 80. Pfizer Business Overview
Table 81. Pfizer Drugs for Oncology Product
Table 82. Pfizer Revenue in Drugs for Oncology Business (2018-2023) & (US$ Million)
Table 83. Pfizer Recent Development
Table 84. Amgen Company Detail
Table 85. Amgen Business Overview
Table 86. Amgen Drugs for Oncology Product
Table 87. Amgen Revenue in Drugs for Oncology Business (2018-2023) & (US$ Million)
Table 88. Amgen Recent Development
Table 89. Eli Lilly Company Detail
Table 90. Eli Lilly Business Overview
Table 91. Eli Lilly Drugs for Oncology Product
Table 92. Eli Lilly Revenue in Drugs for Oncology Business (2018-2023) & (US$ Million)
Table 93. Eli Lilly Recent Development
Table 94. AbbVie Company Detail
Table 95. AbbVie Business Overview
Table 96. AbbVie Drugs for OncologyProduct
Table 97. AbbVie Revenue in Drugs for Oncology Business (2018-2023) & (US$ Million)
Table 98. AbbVie Recent Development
Table 99. Takeda Company Detail
Table 100. Takeda Business Overview
Table 101. Takeda Drugs for OncologyProduct
Table 102. Takeda Revenue in Drugs for Oncology Business (2018-2023) & (US$ Million)
Table 103. Takeda Recent Development
Table 104. Astellas Company Detail
Table 105. Astellas Business Overview
Table 106. Astellas Drugs for OncologyProduct
Table 107. Astellas Revenue in Drugs for Oncology Business (2018-2023) & (US$ Million)
Table 108. Astellas Recent Development
Table 109. Ipsen Company Detail
Table 110. Ipsen Business Overview
Table 111. Ipsen Drugs for OncologyProduct
Table 112. Ipsen Revenue in Drugs for Oncology Business (2018-2023) & (US$ Million)
Table 113. Ipsen Recent Development
Table 114. Sanofi Company Detail
Table 115. Sanofi Business Overview
Table 116. Sanofi Drugs for OncologyProduct
Table 117. Sanofi Revenue in Drugs for Oncology Business (2018-2023) & (US$ Million)
Table 118. Sanofi Recent Development
Table 119. Bayer Company Detail
Table 120. Bayer Business Overview
Table 121. Bayer Drugs for OncologyProduct
Table 122. Bayer Revenue in Drugs for Oncology Business (2018-2023) & (US$ Million)
Table 123. Bayer Recent Development
Table 124. Biogen Idec Company Detail
Table 125. Biogen Idec Business Overview
Table 126. Biogen Idec Drugs for OncologyProduct
Table 127. Biogen Idec Revenue in Drugs for Oncology Business (2018-2023) & (US$ Million)
Table 128. Biogen Idec Recent Development
Table 129. Teva Company Detail
Table 130. Teva Business Overview
Table 131. Teva Drugs for OncologyProduct
Table 132. Teva Revenue in Drugs for Oncology Business (2018-2023) & (US$ Million)
Table 133. Teva Recent Development
Table 134. Otsuka Company Detail
Table 135. Otsuka Business Overview
Table 136. Otsuka Drugs for OncologyProduct
Table 137. Otsuka Revenue in Drugs for Oncology Business (2018-2023) & (US$ Million)
Table 138. Otsuka Recent Development
Table 139. Eisai Company Detail
Table 140. Eisai Business Overview
Table 141. Eisai Drugs for OncologyProduct
Table 142. Eisai Revenue in Drugs for Oncology Business (2018-2023) & (US$ Million)
Table 143. Eisai Recent Development
Table 144. Merck KGaA Company Detail
Table 145. Merck KGaA Business Overview
Table 146. Merck KGaA Drugs for OncologyProduct
Table 147. Merck KGaA Revenue in Drugs for Oncology Business (2018-2023) & (US$ Million)
Table 148. Merck KGaA Recent Development
Table 149. Gilead Sciences Company Detail
Table 150. Gilead Sciences Business Overview
Table 151. Gilead Sciences Drugs for OncologyProduct
Table 152. Gilead Sciences Revenue in Drugs for Oncology Business (2018-2023) & (US$ Million)
Table 153. Gilead Sciences Recent Development
Table 154. Research Programs/Design for This Report
Table 155. Key Data Information from Secondary Sources
Table 156. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Drugs for Oncology Market Share by Type: 2022 VS 2032
Figure 2. Chemotherapy Features
Figure 3. Targeted Therapy Features
Figure 4. Immunotherapy (Biologic Therapy) Features
Figure 5. Hormonal Therapy Features
Figure 6. Others Features
Figure 7. Global Drugs for Oncology Market Share by Application in 2022 & 2032
Figure 8. Blood Cancer Case Studies
Figure 9. Breast Cancer Case Studies
Figure 10. Gastrointestinal Cancer Case Studies
Figure 11. Prostate Cancer Case Studies
Figure 12. Respiratory/Lung Cancer Case Studies
Figure 13. Others Case Studies
Figure 14. Drugs for Oncology Report Years Considered
Figure 15. Global Drugs for Oncology Market Size (US$ Million), Year-over-Year: 2018-2032
Figure 16. Global Drugs for Oncology Market Size, (US$ Million), 2018 VS 2022 VS 2032
Figure 17. Global Drugs for Oncology Market Share by Region: 2022 VS 2032
Figure 18. Global Drugs for Oncology Market Share by Players in 2022
Figure 19. Global Top Drugs for Oncology Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Drugs for Oncology as of 2022)
Figure 20. The Top 10 and 5 Players Market Share by Drugs for Oncology Revenue in 2022
Figure 21. North America Drugs for Oncology Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 22. North America Drugs for Oncology Market Share by Country (2018-2032)
Figure 23. United States Drugs for Oncology Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 24. Canada Drugs for Oncology Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 25. Europe Drugs for Oncology Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 26. Europe Drugs for Oncology Market Share by Country (2018-2032)
Figure 27. Germany Drugs for Oncology Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 28. France Drugs for Oncology Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 29. U.K. Drugs for Oncology Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 30. Italy Drugs for Oncology Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 31. Russia Drugs for Oncology Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 32. Nordic Countries Drugs for Oncology Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 33. Asia-Pacific Drugs for Oncology Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 34. Asia-Pacific Drugs for Oncology Market Share by Region (2018-2032)
Figure 35. China Drugs for Oncology Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 36. Japan Drugs for Oncology Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 37. South Korea Drugs for Oncology Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 38. Southeast Asia Drugs for Oncology Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 39. India Drugs for Oncology Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 40. Australia Drugs for Oncology Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 41. Latin America Drugs for Oncology Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 42. Latin America Drugs for Oncology Market Share by Country (2018-2032)
Figure 43. Mexico Drugs for Oncology Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 44. Brazil Drugs for Oncology Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 45. Middle East & Africa Drugs for Oncology Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 46. Middle East & Africa Drugs for Oncology Market Share by Country (2018-2032)
Figure 47. Turkey Drugs for Oncology Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 48. Saudi Arabia Drugs for Oncology Market Size YoY Growth (2018-2032) & (US$ Million)
Figure 49. Roche Revenue Growth Rate in Drugs for Oncology Business (2018-2023)
Figure 50. Celgene Revenue Growth Rate in Drugs for Oncology Business (2018-2023)
Figure 51. Novartis Revenue Growth Rate in Drugs for Oncology Business (2018-2023)
Figure 52. Bristol-Myers Squibb Revenue Growth Rate in Drugs for Oncology Business (2018-2023)
Figure 53. Johnson & Johnson Revenue Growth Rate in Drugs for Oncology Business (2018-2023)
Figure 54. Merck & Co. Revenue Growth Rate in Drugs for Oncology Business (2018-2023)
Figure 55. AstraZeneca Revenue Growth Rate in Drugs for Oncology Business (2018-2023)
Figure 56. Pfizer Revenue Growth Rate in Drugs for Oncology Business (2018-2023)
Figure 57. Amgen Revenue Growth Rate in Drugs for Oncology Business (2018-2023)
Figure 58. Eli Lilly Revenue Growth Rate in Drugs for Oncology Business (2018-2023)
Figure 59. AbbVie Revenue Growth Rate in Drugs for Oncology Business (2018-2023)
Figure 60. Takeda Revenue Growth Rate in Drugs for Oncology Business (2018-2023)
Figure 61. Astellas Revenue Growth Rate in Drugs for Oncology Business (2018-2023)
Figure 62. Ipsen Revenue Growth Rate in Drugs for Oncology Business (2018-2023)
Figure 63. Sanofi Revenue Growth Rate in Drugs for Oncology Business (2018-2023)
Figure 64. Bayer Revenue Growth Rate in Drugs for Oncology Business (2018-2023)
Figure 65. Biogen Idec Revenue Growth Rate in Drugs for Oncology Business (2018-2023)
Figure 66. Teva Revenue Growth Rate in Drugs for Oncology Business (2018-2023)
Figure 67. Otsuka Revenue Growth Rate in Drugs for Oncology Business (2018-2023)
Figure 68. Eisai Revenue Growth Rate in Drugs for Oncology Business (2018-2023)
Figure 69. Merck KGaA Revenue Growth Rate in Drugs for Oncology Business (2018-2023)
Figure 70. Gilead Sciences Revenue Growth Rate in Drugs for Oncology Business (2018-2023)
Figure 71. Bottom-up and Top-down Approaches for This Report
Figure 72. Data Triangulation
Figure 73. Key Executives Interviewed

DOWNLOAD SAMPLE

Download
Free Sample

Request
Customization

Check
Discount

REPORT PURCHASE OPTIONS

Single User Price : $2762

Multi User Price : $4143

Enterprise Price : $5524

---- OR ----

Frequently Asked Questions ?

Delivery Time

Upto 24 hrs - Working days
Upto 48 hrs max - Weekends and public holidays

User License

Single User License
A license granted to one user. Rules or conditions might be applied for e.g. the use of electric files (PDFs) or printings, depending on product.

Multi user License
A license granted to multiple users.

Site License
A license granted to a single business site/establishment.

Corporate License, Global License
A license granted to all employees within organisation access to the product.

Payment Options

Online Payments with PayPal and CCavenue
Wire Transfer/Bank Transfer

Report Delivery

Email
Hard Copy

Our Key Features

Data Accuracy and Reliability
Data Security
Customized Research
Trustworthy
Competitive Offerings

Global Drugs for Oncology Market Research Report 2023